Oncolytics Biotech (ONCY) Competitors $1.21 0.00 (0.00%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.50%) As of 10/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, AUTL, and CGEMShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Bright Minds Biosciences Lexeo Therapeutics Rapt Therapeutics Autolus Therapeutics Cullinan Therapeutics Oncolytics Biotech (NASDAQ:ONCY) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Does the media favor ONCY or INBX? In the previous week, Oncolytics Biotech had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 6 mentions for Oncolytics Biotech and 3 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.48 beat Oncolytics Biotech's score of 0.42 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, ONCY or INBX? Inhibrx Biosciences has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$23.14M-$0.27-4.48Inhibrx Biosciences$200K2,602.06$1.69B-$10.58-3.40 Do institutionals & insiders hold more shares of ONCY or INBX? 6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate ONCY or INBX? Oncolytics Biotech currently has a consensus target price of $5.00, indicating a potential upside of 313.22%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncolytics Biotech is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Inhibrx Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is ONCY or INBX more profitable? Inhibrx Biosciences' return on equity of -137.83% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -438.11% -143.90% Inhibrx Biosciences N/A -137.83%-76.31% Which has more risk and volatility, ONCY or INBX? Oncolytics Biotech has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. SummaryInhibrx Biosciences beats Oncolytics Biotech on 8 of the 14 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$121.44M$3.36B$6.11B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-4.4822.7785.4027.36Price / SalesN/A483.38599.20137.65Price / CashN/A46.7037.4661.86Price / Book24.2010.5512.446.81Net Income-$23.14M-$52.58M$3.32B$276.80M7 Day Performance-2.42%0.09%0.60%0.42%1 Month Performance-4.72%15.61%10.53%7.86%1 Year Performance-3.20%15.13%73.12%41.24% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.9485 of 5 stars$1.21flat$5.00+313.2%-2.4%$121.44MN/A-4.4830INBXInhibrx Biosciences1.7261 of 5 stars$34.38+5.9%N/A+128.3%$470.27M$200K-3.25166ATXSAstria Therapeutics2.2045 of 5 stars$8.47+1.9%$29.50+248.3%+3.7%$468.97MN/A-4.2130Trending NewsAnalyst DowngradeCYRXCryoPort3.6519 of 5 stars$9.40+1.1%$12.56+33.6%+35.5%$465.62M$228.38M7.071,186Gap UpSLDBSolid Biosciences2.8007 of 5 stars$6.01+0.8%$15.00+149.6%-4.7%$464.10M$8.09M-2.15100ALMSAlumis3.5648 of 5 stars$4.61+3.8%$20.17+337.5%-56.7%$462.05MN/A0.00N/APositive NewsDRUGBright Minds Biosciences3.0161 of 5 stars$64.97+2.7%$81.00+24.7%+76.8%$445.81MN/A-69.86N/ANews CoveragePositive NewsAnalyst UpgradeLXEOLexeo Therapeutics2.8101 of 5 stars$8.20-0.5%$17.00+107.3%-1.1%$444.97M$650K-2.5258Analyst ForecastGap UpRAPTRapt Therapeutics3.3674 of 5 stars$26.35-1.6%$24.78-6.0%+86.7%$443.05M$1.53M-1.8680Analyst ForecastAnalyst RevisionAUTLAutolus Therapeutics3.421 of 5 stars$1.65-0.6%$9.12+452.7%-59.6%$441.80M$10.12M-1.96330Gap UpCGEMCullinan Therapeutics3.2983 of 5 stars$7.83+5.8%$26.00+232.1%-46.9%$437.15MN/A-2.4230News CoveragePositive News Related Companies and Tools Related Companies Inhibrx Biosciences Competitors Astria Therapeutics Competitors CryoPort Competitors Solid Biosciences Competitors Alumis Competitors Bright Minds Biosciences Competitors Lexeo Therapeutics Competitors Rapt Therapeutics Competitors Autolus Therapeutics Competitors Cullinan Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
